Clinical trials: Digestive System
Hemorrhoids
Prevention and/or Reduction of Hemorrhoids and/or Thrombosed External Hemorrhoids Using the HEM-AVERT Perianal Stabilizer Instrument
This study is being conducted to evaluate an investigational instrument called the HEM-AVERT Perianal Stabilizer and its efficacy in reducing the occurrence or severity of hemorrhoids and thrombosed external hemorrhoids (TEH)…
- Trial name
- HEM-AVERT (NCT00487045)
- Testing
- Hem-Avert Perianal Stabilizer
- Where
- 3 sites in United States
- Volunteers
- 176 people
- Sponsor
- Stetrix, Inc.
Metastatic Cancer, Cancer
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
The goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer.
- Conditions
- Metastatic Cancer, Cancer, Solid Tumors
- Trial name
- NCT01300533
- Testing
- BIND-014
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- BIND Therapeutics
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study)
Ulcerative colitis is a condition that causes inflammation and ulcers in the large intestine. MGT-006 is an investigational oral capsule containing viable gut microbiota from screened human donors.
- Trial name
- ROOT (NCT07913347)
- Testing
- MGT-006, Vancomycin hydrochloride, Amoxicillin hydrate/ Fosfomycin calcium hydrate/ Metronidazole
- Where
- 12 sites in United States, Japan
- Volunteers
- 54 people
- Sponsor
- Metagen Therapeutics, Inc.
Lung Cancer, Colorectal Cancer
ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population
This is a prospective, multi-centre interventional study evaluating the feasibility of blood-based multi-cancer early detection test in asymptomatic screening cohort.
- Conditions
- Lung Cancer, Colorectal Cancer, Liver Cancer, Grastic Cancer
- Trial name
- NCT06790355
- Testing
- multi-cancer early detection
- Where
- 4 sites in China
- Volunteers
- 2,527 people, healthy volunteers welcome
- Sponsor
- Shanghai Weihe Medical Laboratory Co., Ltd.
Chronic Hepatitis C
Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C
This study is being conducted in treatment-naive patients (no previous hepatitis C treatment) to evaluate the safety of valopicitabine (NM283) alone and together with pegylated interferon, a drug approved by the Food and Drug…
- Trial name
- NCT00120835
- Testing
- valopicitabine, pegylated interferon
- Where
- 3 sites in United States, Puerto Rico
- Sponsor
- Merck Sharp & Dohme LLC
Cystic Fibrosis
Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients
Prospective, randomized, placebo controlled, phase II clinical study of subjects crossing over from an approved inhaled antibiotic to inhaled nitric oxide as compared to a placebo control arm.
- Trial name
- NCT02498535
- Testing
- Nitric Oxide 160 ppm
- Where
- 7 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- Novoteris, LLC
Liver Cancer
DX-8951f in Treating Patients With Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have liver cancer.
- Trial name
- NCT00004108
- Testing
- exatecan mesylate
- Where
- 4 sites in United States
- Sponsor
- Daiichi Sankyo
Advanced or Metastatic Colorectal Cancer (mCRC)
Individual Patient Expanded Access to CA102N
This study is an individual patient expanded access protocol that the subject enrolled had completed the combination treatment of CA102N plus Lonsurf for at least 12 cycles.
- Trial name
- NCT05274204
- Testing
- CA102N
- Sponsor
- Holy Stone Healthcare Co., Ltd
Acute on Chronic Liver Failure (ACLF), Hepatic Encephalopathy (HE)
RENEW: Study of Porcine Liver Support in Participants With Acute-on-Chronic Liver Failure
This is a Phase 1/2, first-in-human (FIH) safety, proof-of-concept, two-part study of the genetically-engineered EGEN-5784 liver in combination with the metra® extra-corporeal liver cross-circulation (ELC) system in participants…
- Trial name
- NCT07429838
- Testing
- metra® Extracorporeal Liver Cross-Circulation (ELC) system (OrganOx), EGEN-5784 (genetically engineered porcine liver)
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- eGenesis, INC
Hepatitis C
Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy
The purpose of this study is to determine if treatment with Pegylated Interferon Lambda-1a, given in combination with Ribavirin and Daclatasvir for 24 weeks, is as safe and effective as the standard treatment with Pegylated…
- Trial name
- STRUCTURE (NCT01718158)
- Testing
- Peginterferon Lambda-1a, Peginterferon Alfa-2a, Ribavirin
- Where
- 78 sites in United States, Argentina and 11 more
- Volunteers
- 444 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic
Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)
This study is an open-label, multi-center trial to evaluate the novel 2-drug regimen of uprifosbuvir (MK-3682) 450 mg and ruzasvir (MK-8408) 60 mg in participants with chronic hepatitis C virus (HCV) genotype (GT)1, GT2, GT3…
- Trial name
- NCT02759315
- Testing
- Uprifosbuvir 450 mg, Ruzasvir 60 mg
- Volunteers
- 160 people
- Sponsor
- Merck Sharp & Dohme LLC
Diverticulitis
Prevention of Recurrence of Diverticulitis
The purpose of this study is to determine whether SPD476 is effective in reducing recurrence of diverticulitis.
- Trial name
- PREVENT1 (NCT00545740)
- Testing
- SPD476 (1.2g), SPD476 (2.4 g), SPD476 (4.8 g)
- Where
- 121 sites in United States, Argentina and 9 more
- Volunteers
- 590 people
- Sponsor
- Shire
Neuroblastoma in Children, Neuroblastoma, Recurrent, Refractory
Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
This is an Expanded Access Program (EAP) that will give the participants access to the drug SL-28 before it is approved by the FDA.
- Conditions
- Neuroblastoma in Children, Neuroblastoma, Recurrent, Refractory, Advanced Cancer, Advanced Malignant Neoplasm
- Trial name
- NCT06872489
- Testing
- SL-28.
- Sponsor
- Second Life Therapeutics
Hepatic Insufficiency
Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency
This clinical pharmacology research study will assess the safety and pharmacokinetics of the drug everolimus in patients with impaired hepatic function as compared to healthy volunteers.
- Trial name
- NCT00968591
- Testing
- Everolimus
- Where
- 3 sites in Germany, Russia and 1 more
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)
This is a Phase 2, multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy on TVB-2640 in subjects with non-alcoholic steatohepatitis (NASH).
- Trial name
- NCT04906421
- Testing
- TVB-2640
- Where
- 117 sites in United States, Canada and 2 more
- Volunteers
- 168 people
- Sponsor
- Sagimet Biosciences Inc.
Benign Esophageal Lesions
SX ELLA Esophageal Degradable BD Stent System
The SX-ELLA Stent Esophageal Degradable BD (BD Stent) is designed for dilation of benign esophageal lesions, namely: (1) stenosis (peptic, anastomotic or caustic) refractory to standard therapy, (2) achalasia refractory to…
- Trial name
- DESTINY (NCT01337206)
- Testing
- Stenting with ELLA Biodegradable stent, Standard Dilations
- Where
- 8 sites in Belgium, Italy and 3 more
- Volunteers
- 66 people
- Sponsor
- Cook Group Incorporated
Gastric Ulcer
A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)
This study uses an open-label design and will be conducted in approximately 60 sites aiming to enroll a total number of 200 subjects to ensure that at least 100 subjects will have 12 months exposure to PN400 (VIMOVO).
- Trial name
- NCT00527904
- Testing
- PN400 (VIMOVO), PN 400 (VIMOVO)
- Where
- United States
- Volunteers
- 239 people
- Sponsor
- POZEN
Irritable Bowel Syndrome, Gastrointestinal Diseases
Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome
The objective of this randomized, double-blind, placebo-controlled study is to evaluate the effectiveness of Skal Pro in alleviating symptoms, enhancing stool consistency, improving quality of life, and addressing psychological…
- Conditions
- Irritable Bowel Syndrome, Gastrointestinal Diseases, Colonic Diseases, Functional, Intestinal Disease
- Trial name
- NCT06271538
- Testing
- Skal Pro
- Where
- Malaysia
- Volunteers
- 57 people
- Sponsor
- EP Plus Group Sdn Bhd
Ulcerative Colitis
A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Ulcerative Colitis
The purpose of this study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with Ulcerative Colitis.
- Trial name
- NCT00096655
- Testing
- Infliximab
- Volunteers
- 364 people, healthy volunteers welcome
- Sponsor
- Centocor, Inc.
Gastroparesis
Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis
This is a multicenter, randomized, double-blind, incomplete block, three period fixed sequence crossover, multicenter, placebo-controlled study.
- Trial name
- NCT01718938
- Testing
- velusetrag dose 1, velusetrag dose 2, velusetrag dose 3
- Where
- 9 sites in United States
- Volunteers
- 34 people
- Sponsor
- Theravance Biopharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.